Claro Advisors LLC Acquires 251 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Claro Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 110.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 478 shares of the biopharmaceutical company’s stock after purchasing an additional 251 shares during the quarter. Claro Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $502,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Concord Asset Management LLC VA increased its position in Regeneron Pharmaceuticals by 16.7% in the 3rd quarter. Concord Asset Management LLC VA now owns 1,064 shares of the biopharmaceutical company’s stock worth $1,119,000 after buying an additional 152 shares during the period. Atlanta Consulting Group Advisors LLC bought a new position in Regeneron Pharmaceuticals during the third quarter worth $534,000. Schear Investment Advisers LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at $397,000. Natixis Advisors LLC raised its stake in Regeneron Pharmaceuticals by 0.3% during the 3rd quarter. Natixis Advisors LLC now owns 117,002 shares of the biopharmaceutical company’s stock valued at $122,997,000 after purchasing an additional 319 shares during the last quarter. Finally, Mizuho Securities USA LLC boosted its holdings in Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after purchasing an additional 51,162 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on REGN shares. Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, Piper Sandler reduced their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,099.55.

Insiders Place Their Bets

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $762.00 on Tuesday. The stock has a 50-day simple moving average of $977.55 and a 200 day simple moving average of $1,033.65. The stock has a market capitalization of $83.74 billion, a price-to-earnings ratio of 18.86, a P/E/G ratio of 2.86 and a beta of 0.15. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $750.20 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.